About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Infection and Immunity in pediatric patients research group is a multidisciplinary pediatric research group made up of health professionals involved in translational research in the field of pediatric infectious diseases and immunodeficiencies, two related fields in terms of pathophysiology and clinical implications. It is a consolidated research group recognized by the AGAUR and is the only one with the accreditation of the Jeffrey Modell Foundation in research in the field of primary immunodeficiencies throughout the state.
The group was officially created in 2010, belongs to the area of Infectious Diseases and participates in the transversal programs of Advanced Translational Immunology and Rare Diseases and actively participates in national and international competitive projects, carries out multiple academic and industry-linked clinical trials and has increased the number and quality in recent years. In addition, it has its own laboratory specially dedicated to advanced immune studies.
IP: Pere Soler Palacín
IP: Pere Soler Palacín Collaborators: Laura Batlle Masó, Maria Cristina Díaz de Heredia Rubio, Roger Colobran Oriol, Thaïs Murciano Carrillo, Constantino Sábado Álvarez, Miriam Gonzalez Amores, Janire Perurena Prieto, Andrea Martín Nalda, Lucas Moreno Martín-Retortillo, Jacques Gabriel Rivière Funding agency: Instituto de Salud Carlos III Funding: 179993.75 Reference: AC23_2/00033 Duration: 01/01/2024 - 31/12/2026
IP: Roger Colobran Oriol Collaborators: Romina Dieli Crimi, Aina Aguiló Cucurull, Laura Batlle Masó, Andrea Martín Nalda, Identification and functional characterization of structural variants in patients with inborn errors of immunity Funding agency: Instituto de Salud Carlos III Funding: 208750 Reference: PI23/00161 Duration: 01/01/2024 - 30/06/2028
IP: Andres Antón Pagarolas Collaborators: Sistema integral para la vigilancia clínica, epidemiológica y microbiológica (SiVEV/BCN) de la enfermedad asociada a enterovirus, Jorgina Vila Soler, Yolima Cossio Gil, Rocío Rodrigo García, Tomàs Pumarola Suñé, Maria Espiau Guarner, Núria Worner Tomasa, Maria Piñana Moro, Ariadna Carsi Durall, Anna Creus Costa, Alejandra Gonzalez Sánchez, Cristina Andrés Vergés, Narcís Saubí Roca, Allisson Dantas De Oliveira Funding agency: Instituto de Salud Carlos III Funding: 214170 Reference: PI22/00023 Duration: 01/01/2023 - 30/06/2026
IP: Juan Jose Gonzalez Lopez Collaborators: Manuel Hernández González, Jose Angel Rodrigo Pendás, Maria Belén Viñado Perez, Aina Aguiló Cucurull, Laura Batlle Masó, Alba Mir Cros, Nuria Serre Delcor, Albert Moreno Mingorance, Josep Roca Grande, Andrea Martín Nalda Funding agency: Instituto de Salud Carlos III Funding: 123420 Reference: PI21/00132 Duration: 01/01/2022 - 30/06/2026
The vaccine activates both antibody production and the T-cell response, maintaining, for at least one year, a higher immune response than before vaccination.
The initiative focuses on awareness, prevention, and the normalization of sexual health check-ups among young people.
The meeting, held in Barcelona, provided an opportunity to present the project's main findings and establish new avenues of collaboration among the consortium members.
